← Search another drug
PatientPulse · by PatientPartner
Xtandi enzalutamide
High confidence
Approximately 59 public patient conversations and reviews referenced across forums (HealthUnlocked, HealingWell, Inspire, Prostate Cancer UK), patient blogs, Mayo Clinic Connect, Drugs.com, and health news sources.
Executive intelligence
The signal that moves starts & adherence
38%Positive sentiment in discussion
58,003FDA adverse-event reports
62%Flagged serious
1%Reports name female patients
The ARACOG head-to-head trial showing darolutamide causes roughly half the cognitive decline of enzalutamide is the single biggest near-term commercial threat to Xtandi retention among newly diagnosed patients with any cognitive concerns.
- Fatigue and brain fog dominate the Xtandi patient conversation, frequently prompting dose self-reduction from 160 mg to 80-120 mg as patients try to preserve quality of life without abandoning PSA control.
- Out-of-pocket cost shock (often $1,500 to $3,300 for a first fill) is a distinct adherence-breaking event, with patients reporting forced treatment gaps and active switching inquiries to lower-cost generics like abiraterone.
- A vocal minority (estimated 6-8% in community posts) experience debilitating side effects including confusion, edema, and severe asthenia that force discontinuation, while a broader majority report manageable but persistent fatigue they have learned to accommodate.
- The ARACOG Phase II trial presented at ASCO 2026 showing darolutamide produced significantly less cognitive decline than enzalutamide is crystallizing patient-level switching conversations already visible in HealthUnlocked community threads.